Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02509234

Trabectedin and Irinotecan for Refractory Pediatric Sarcomas — TrIPReSarc  

Recurrent Childhood Soft Tissue Sarcoma Clinical Trial

Official title:
Trabectedin and Irinotecan in Pediatric Refractory Sarcomas

Clinical Trial Summary

The purpose of the study is to evaluate patients with refractory childhood sarcomas, who have been treated with a combination therapy of trabectedin and irinotecan (within compassionate use), to determine, if this is a promising treatment option with acceptable toxicity and if the results warrant a prospective study.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02509234
Study type Observational
Source Technische Universität München
Contact
Status Active, not recruiting
Phase N/A
Start date February 2014
Completion date July 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT00093821 - Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors Phase 1
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT00091182 - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Phase 2
Completed NCT00030667 - Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Phase 2
Recruiting NCT01567046 - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas N/A
Completed NCT00101270 - Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Completed NCT00919269 - Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Active, not recruiting NCT03210714 - Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT00929903 - Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Phase 1
Completed NCT00720174 - Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Phase 1
Completed NCT01614795 - Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Phase 2
Completed NCT00831844 - Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Phase 2
Completed NCT00070109 - Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Phase 2
Recruiting NCT05857969 - Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Completed NCT03860376 - Ex Vivo Drug Sensitivity Testing and Mutation Profiling
Completed NCT01154816 - Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Phase 2
Completed NCT00077454 - Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors Phase 1
Completed NCT00331643 - Ixabepilone in Treating Young Patients With Refractory Solid Tumors Phase 2
Completed NCT00012181 - Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Phase 1